LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study ...

Auricular vagal neuromodulation therapy is a non-invasive and non-surgical treatment that could aid cardiovascular disease ...

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the ...

VNS Therapy has not been approved by the U.S. Food and Drug Administration (FDA) for use in primary generalized seizures, and the safety and effectiveness of VNS Therapy for the reduction of primary ...

Credit: Getty Images. Research indicates that stimulation of the left vagus nerve have been shown to improve depression symptoms. Vagus nerve stimulation is now being revisited as an adjunct treatment ...

– Effective Jan. 1, 2026, will improve economics for hospitals performing Medicare procedures and significantly reduces a known barrier to procedure penetration LONDON, November 24, 2025--(BUSINESS ...

In a first-of-its-kind clinical study, scientists at The University of Texas at Dallas and Baylor University Medical Center showed that patients with treatment-resistant PTSD were symptom-free up to ...

Want to stay on top of your wellness in 2026? These are the trends you need to know about, according to industry experts.

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with ...